Sulfathiazole Granule

In commercial swine and poultry operations, the incorporation of sulfathiazole granules into dry meal or pelleted rations requires precise gravimetric dosing to meet therapeutic targets without exceeding maximum residue limits (MRLs) established under Commission Regulation (EU) No 37/2010, where the sum of all sulfonamides in edible tissues is capped at 100 µg/kg, and under 21 CFR 556.660, which sets the tolerance for sulfathiazole residues in uncooked edible tissues of cattle at 0.1 ppm. The granule form, typically characterized by a particle size distribution (PSD) with 90% by mass falling between 150 µm and 800 µm and a bulk density of 0.55–0.75 g/cm³, is selected to minimise segregation during pneumatic conveying and ribbon blending when admixed with ground corn cob or limestone carrier. A stepwise mixing protocol is employed: a preliminary 1:10 preblend of sulfathiazole granules and a carrier of similar particle morphology is prepared in a tumble blender, then this intermediate blend is introduced into a horizontal ribbon mixer alongside micro-ingredients and the basal ration at a final incorporation rate of 200–400 g active sulfathiazole per tonne of complete feed for a 5–7 day therapeutic regimen targeting porcine atrophic rhinitis or avian fowl cholera. Homogeneity is verified according to ISO 6497:2005 using at least 10 stratified samples drawn from the mixer dead zones; a coefficient of variation (CV) below 7% is mandated, with values above 10% triggering a root-cause investigation into blade clearance, fill level, or static charge accumulation. When the medicated mash is subsequently conditioned and pelleted through a ring die press, the conditioning temperature is strictly maintained below 80 °C and residence time kept under 45 seconds, as polymorphic transition in crystalline sulfathiazole has been documented at sustained thermal input above 85 °C leading to a shift in dissolution profile. The terminal product is a medicated complete feed or a 25 kg multi-wall paper bag of veterinary premix intermediate, labelled with the batch-specific homogeneity data and a shelf-life of 6 months under storage conditions not exceeding 25 °C and 60% relative humidity.

What Limits Dissolution Rate and Water Stability in High-Potency Sulfathiazole Soluble Powders?

Formulation of a drinking-water-soluble powder from sulfathiazole granules confronts the inherent low aqueous solubility of the free acid form, which is approximately 1 g/L at 25 °C and pH 7.0. To achieve a target in-drinking-water concentration of 1 g/L active moiety equivalent to a daily dose of 30 mg/kg bodyweight in poultry, the granules are first dry-milled using a pin mill to a Dv90 of < 50 µm and then blended with a solubilising aid—anhydrous sodium carbonate or trisodium citrate at a mole ratio of 1:1.2 relative to sulfathiazole—inside a twin-shell V-blender operated at 70% of rated capacity for 25 minutes. The resultant bulk powder, standardised to 50% w/w sulfathiazole activity, is filled into foil-lined sachets under conditions of relative humidity below 30% to prevent premature carbon dioxide evolution. Compliance with VICH GL18 guidance on bioequivalence for oral soluble powders requires a dissolution test per Ph. Eur. 2.9.3 using 900 mL of phosphate buffer pH 6.8 at 37 °C with paddle apparatus at 50 rpm, where not less than 80% of the labelled amount must dissolve within 30 minutes. Hard water with a total hardness above 250 ppm as CaCO₃ can complex sulfathiazole and reduce dissolution rate by up to 15%; therefore, the formula often incorporates a chelating agent such as EDTA disodium at 0.5% w/w. The finished product is a veterinary soluble powder packaged in 1 kg or 5 kg heat-sealed aluminium laminate sachets for on-farm administration via a proportional medicator pump calibrated to deliver a 1–2% stock solution.

For parenteral depot preparations intended for bacterial pneumonia in feedlot cattle, sulfathiazole granules are micronised using a fluidised-bed opposed-jet mill with a classifier rotor speed set to 8,500 rpm to yield a Dv90 of < 10 µm and a Dv50 of < 4 µm, as larger particles cause needle occlusion when injected through 18-gauge needles and can provoke injection-site granulomas. The micronised powder is suspended in a non-aqueous vehicle composed of medium-chain triglycerides and 2.5% w/v aluminium monostearate as a thixotropic structurant, with 0.3% w/v polysorbate 80 as a wetting agent; the suspension is passed through a high-pressure homogeniser at 600 bar for three discrete passes until the viscosity at 0.1 s⁻¹ shear rate reaches 1,200–1,800 mPa·s. Terminal sterilisation is accomplished by moist-heat autoclaving at 121 °C for 15 minutes in a rotary cycle to keep the drug uniformly dispersed; however, a post-sterilisation increase in mean particle size of up to 20% due to Ostwald ripening has been documented, which necessitates the addition of a crystal growth inhibitor—hypromellose at 0.1% w/w of the oil phase. Sterility assurance is validated against Ph. Eur. 5.1.1 and endotoxin limits are capped at 0.5 EU/mg per Ph. Eur. 2.6.14. The filled product is a 100 mL multidose flint glass vial sealed with a bromobutyl rubber stopper, containing 20% w/v sulfathiazole suspension, labelled for intramuscular administration at a dose of 15 mg/kg bodyweight once every 24 hours for up to 4 days.

Oral Bolus Manufacture and the Effect of Granule Particle Size on Compact Tensile Strength

Sulfathiazole granules are the starting material for producing oral tablets and large-unit boluses intended for sheep and cattle, where a dose of 5 g active per bolus is standard for treating enteric colibacillosis. Direct compression of the as-received granules is rarely feasible because their median particle size of 350 µm leads to poor die filling and tablet tensile strengths below 1.0 MPa as measured by a diametral compression test following USP <1217>. Consequently, a wet granulation step is introduced: the granules are de-agglomerated in a cone mill fitted with a 1.0 mm rasp screen, blended with 5% w/w povidone K30 and 10% w/w microcrystalline cellulose PH-102 in a high-shear mixer-granulator, and granulated with purified water at a liquid-to-solid ratio of 0.25. The wet mass is dried in a fluid-bed dryer at an inlet air temperature of 60 °C until a loss-on-drying of 1.5–2.0% is achieved, then dry-screened through a 1.25 mm oscillating sieve. Tablets are compressed on a rotary press to a hardness of 8–12 kp (Schleuniger), resulting in a friability below 0.5% per Ph. Eur. 2.9.7 and a disintegration time of less than 15 minutes in simulated ruminal fluid per Ph. Eur. 2.9.1. The final bolus, often a rectangular flat-faced tablet of 7 g total weight, is packed in a cold-form aluminium foil blister to exclude moisture and is accompanied by a plastic balling gun applicator. Regulatory acceptability references the monograph for sulfathiazole tablets of the British Pharmacopoeia (Veterinary), which demands an assay by HPLC of 95.0–105.0% of the declared content and limits total related substances to 1.5%.

When Sulfathiazole Granules Are Co-Processed with Trimethoprim in Fixed-Dose Combination Premixes

A synergistic fixed-dose combination of sulfathiazole and trimethoprim (TMP) at a potency ratio of 5:1 is widely utilised in porcine and poultry feed to combat a broad spectrum of Gram-positive and Gram-negative pathogens, exploiting the sequential blockade of dihydropteroate synthetase and dihydrofolate reductase. Manufacturing begins with two separate preblends: sulfathiazole granules are adsorbed onto pregelatinised starch in a pneumatic conveying loop to a uniformity of ≤ 5% CV, while trimethoprim is spray-dried onto a colloidal silica carrier to enhance its flowability, given its cohesive nature. The two preblends are then combined in a double-ribbon mixer and further diluted with a ground rice hull carrier to yield a final premix containing 25% w/w sulfathiazole and 5% w/w trimethoprim. The addition rate to complete feed is calculated to deliver 5 mg TMP + 25 mg sulfathiazole per kg bodyweight per day, equivalent to approximately 1 kg of premix per tonne of feed for pigs. Cross-contamination control complies with GMP+ B3 feed safety assurance and validated cleaning procedures using a riboflavin-based visual residue test; sulfathiazole carryover into a non-medicated batch must be below 1% of the therapeutic dose as per EMA/CVMP/914/2020 guidance on minimizing antimicrobial resistance risk. The finished premix is packed in 20 kg antistatic polyethylene-lined bags and is supplied with a certificate of analysis that details homogeneity data from 15 sampling points as per ISO 6498:2012.

Aseptic intramammary infusion formulations for dry-cow therapy constitute a distinct downstream application where sulfathiazole granules are processed into a sterile, long-acting suspension. The granules are pre-sterilised by gamma irradiation at a dose of 25 kGy, validated to a sterility assurance level of 10⁻⁶ per ISO 11137-2:2013. The irradiated powder is aseptically dispersed in a vehicle of fractionated coconut oil thickened with 3% w/w glyceryl behenate, using a recirculating rotor-stator mixer operated under a unidirectional laminar airflow cabinet. The suspension is filled into high-density polyethylene udder injectors delivering a 10 mL dose containing 500 mg sulfathiazole. Potency is confirmed against a standardised bacterial challenge of Streptococcus agalactiae by a modified growth inhibition assay per Ph. Eur. 5.1.6 alternative sterility testing. The terminal product is a box of 24 single-dose syringes, labelled with a withdrawal period of 96 hours for milk and 28 days for meat, in accordance with the MRL schedules of Commission Regulation (EU) No 37/2010.